Sands Capital Ventures Discovery Fund III, L.P. - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: 10%+ Owner
Signature: /s/ Jonathan Goodman, General Counsel of Sands Capital Ventures Discovery Fund III-GP, LLC, the General Partner of Sands Capital Ventures Discovery Fund III, L.P.
Stock symbol: ABOS
Transactions as of: Jul 6, 2021
Transactions value $: $6,696,000
Form type: 4
Date filed: 7/8/2021, 05:21 PM
Previous filing: Jun 30, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+1.12M			1.12M	Jul 6, 2021	Direct	F1, F3, F5
transaction	ABOS	Common Stock	Conversion of derivative security		+1.84M	+163.8%		2.97M	Jul 6, 2021	Direct	F1, F4, F5
transaction	ABOS	Common Stock	Purchase	$6.7M	+450K	+15.17%	$14.88	3.42M	Jul 6, 2021	Direct	F2, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series A-1 Preferred Stock	Conversion of derivative security		-1.12M	-100%		0	Jul 6, 2021	Common Stock	1.12M		Direct	F1, F3, F5
transaction	ABOS	Series B Preferred Stock	Conversion of derivative security		-1.84M	-100%		0	Jul 6, 2021	Common Stock	1.84M		Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sands Capital Ventures Discovery Fund III, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
F2	Represents 225,000 shares of Common Stock acquired by Sands Capital Global Venture Fund II, L.P. ("Sands Venture Fund") and 225,000 shares of Common Stock acquired by ands Capital Life Sciences Pulse Fund ("Sands Pulse Fund") in connection with the closing of the Issuer's initial public offering.
F3	Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F4	Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein.
F5	Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.